---
title: "Bausch + Lomb | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1.244 B"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284553992.md"
datetime: "2026-04-29T11:04:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284553992.md)
  - [en](https://longbridge.com/en/news/284553992.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284553992.md)
---

# Bausch + Lomb | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1.244 B

Revenue: As of FY2026 Q1, the actual value is USD 1.244 B, beating the estimate of USD 1.216 B.

EPS: As of FY2026 Q1, the actual value is USD -0.2, missing the estimate of USD -0.1475.

EBIT: As of FY2026 Q1, the actual value is USD 126 M.

#### Total Revenue

Bausch + Lomb Corporation reported total revenue of $1.244 billion for the first quarter of 2026, an increase of $107 million, or 9%, compared to $1.137 billion in the first quarter of 2025. On a constant currency basis, revenue grew approximately 6% compared to the first quarter of 2025 .

#### Segment Revenue

-   **Vision Care**: Revenue was $711 million for the first quarter of 2026, up $55 million or 8% from $656 million in the first quarter of 2025. Excluding foreign exchange impacts, segment revenue increased by approximately 5% on a constant currency basis, driven by sales from over-the-counter dry eye products, LUMIFY®, and SiHy Daily lenses .
-   **Surgical**: Revenue reached $228 million in the first quarter of 2026, an increase of $14 million or 7% from $214 million in the first quarter of 2025. On a constant currency basis, segment revenue increased by approximately 1%, primarily due to growth in premium IOLs and consumables .
-   **Pharmaceuticals**: Revenue was $305 million for the first quarter of 2026, marking an increase of $38 million or 14% from $267 million in the first quarter of 2025. On a constant currency basis, segment revenue grew by approximately 12%, largely driven by increased sales of MIEBO® (+33%) and XIIDRA® (+30%), and growth in International Pharmaceuticals .

#### Operating Income

Operating income for the first quarter of 2026 was $33 million, a favorable change of $116 million compared to an operating loss of - $83 million in the first quarter of 2025. This change was attributed to revenue performance and operating efficiencies .

#### Net Loss Attributable to Bausch + Lomb Corporation

Net loss attributable to Bausch + Lomb Corporation was - $71 million for the first quarter of 2026, a favorable change of $141 million from - $212 million in the first quarter of 2025. This improvement was primarily due to increased operating results and a favorable change in the provision for income taxes .

#### Adjusted Net Income (non-GAAP)

Adjusted net income attributable to Bausch + Lomb Corporation (non-GAAP) was $19 million in the first quarter of 2026, a favorable change of $73 million from an adjusted net loss of - $54 million in the first quarter of 2025 .

#### Cash Flow from Operations

Cash flow from operations for the first quarter of 2026 was $32 million, a favorable change of $57 million compared to cash flow used in operations of - $25 million in the first quarter of 2025. The positive impact was linked to operating results .

#### Adjusted EBITDA (non-GAAP)

Adjusted EBITDA (non-GAAP) was $189 million for the first quarter of 2026, an increase of $91 million from $98 million in the first quarter of 2025. Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) was $200 million for the first quarter of 2026, an increase of $74 million from $126 million in the first quarter of 2025. These increases were driven by revenue performance and operating efficiencies .

#### Balance Sheet Highlights

As of March 31, 2026, Bausch + Lomb Corporation held $279 million in cash, cash equivalents, and restricted cash .

#### 2026 Financial Outlook

Bausch + Lomb Corporation raised its full-year 2026 guidance for both revenue and Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP) . The company now expects full-year revenue to be between $5.420 billion and $5.520 billion, with constant currency growth projected at 5.3% to 7.2% . Full-year Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP) is anticipated to range from $1.010 billion to $1.060 billion .

### Related Stocks

- [BLCO.US](https://longbridge.com/en/quote/BLCO.US.md)

## Related News & Research

- [Better Futures raises EUR 600,000 from Enterprise Ireland, angel investors](https://longbridge.com/en/news/287057631.md)
- [Bausch + Lomb Q1 revenue rises 9%, beats estimates; lifts 2026 outlook](https://longbridge.com/en/news/284554423.md)
- [Dear Future SpaceX (SPCX) Stock Fans, Mark Your Calendars for June 12](https://longbridge.com/en/news/286809659.md)
- [Auburn National Bancorporation declares $0.27 quarterly dividend payable June 25](https://longbridge.com/en/news/286281680.md)
- [Dear D-Wave Quantum Stock Fans, Mark Your Calendars for May 12](https://longbridge.com/en/news/285977949.md)